SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (12011)12/28/2018 11:43:47 AM
From: scaram(o)uche1 Recommendation

Recommended By
rkrw

  Respond to of 12215
 
Major shareholder dumping into market, largest blocks to fall have been under 100k.

So I consider it a real possibility, and watch diligently.... would continue to add to position. But I'd say "no", if the AFM11 trial restarts and flushes out shares. Deep under two would be a silly discount to cash, low burn company. But, again, paper losses never get to me (except when it's due to management ineptitude, which everyone here knows).



To: Miljenko Zuanic who wrote (12011)12/28/2018 2:21:36 PM
From: semi_infinite 1 Recommendation

Recommended By
scaram(o)uche

  Respond to of 12215
 
I suppose it is possible given enough time and bad clinical outcomes. Closing price prior to Roche news was 1.65 and the upfront cash was ~ 1.5 per share so the step change was not based upon non-cash optimism alone. Perhaps this will be in the ~10% of gaps where there is no round trip plus recent market action gave it ample chances for wash out selling. IMO it could a playable bounce FWIW.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News